TPTX » Topics » About Daewoong Pharmaceutical Company Ltd.

This excerpt taken from the TPTX 8-K filed Jan 6, 2006.

About Daewoong Pharmaceutical Company Ltd.

Daewoong Pharmaceutical is the leading pharmaceutical company in the Korean prescription drug market which has a solid network in the sales and marketing field. Daewoong has 9 products of which sales is over $10 million, meaning the company with the largest number of Korean blockbuster products.

Daewoong group also deals with OTC, raw material and IT related business through its subsidiaries. For the fiscal year ended March 31, 2005, Daewoong pharmaceutical generated revenues of over $350 million, while the Daewoong group generated revenues of over $500 million.

In 2001, Daewoong has succeeded to develop and launch Easyef (Epidermal Growth Factor), the first bioengineering product in Korea, indicated for the diabetic foot ulcer. Additional clinical trial are being conducted for the extension of indication into the general wound healing area. In 2003, Daewoong is succeeded to synthesis of the Coenzyme Q10 at the second time in the world and exporting raw material to all over the world. Daewoong is also developing an early stage of several new chemical entities.

The company is headquartered in Seoul, South Korea.

This press release may contain forward-looking statements or predictions. These statements represent our judgment to date, and are subject to risks and uncertainties that could materially affect the Company, including those risks and uncertainties described in the documents Axonyx files from time to time with the SEC, specifically Axonyx’s annual report on Form 10-K. Specifically, with respect to our drug candidates Phenserine, Posiphen™ and BisNorCymcerine, Axonyx cannot assure that: any preclinical studies or clinical trials, whether ongoing or conducted in the future, will prove successful, and if successful, that the results can be replicated; safety and efficacy profiles of any of its drug candidates will be established, or if established, will remain the same, be better or worse in future clinical trials, if any; pre-clinical results related to cognition and the regulation of beta-APP will be substantiated by ongoing or future clinical trials, if any, or that any of its drug candidates will be able to improve the signs or symptoms of their respective clinical indication or slow the progression of Alzheimer’s disease; any of its drug candidates will support an NDA filing or its equivalent, will be approved by the FDA or its equivalent, or if approved, will prove competitive in the market; or that Axonyx will have or obtain the necessary financing to support its drug development programs. Axonyx cannot assure that it will be successful with regard to identifying a (sub-) licensing partner for any of its compounds, or that any such partner will successfully develop or commercialize any such compound. Axonyx undertakes no obligation to publicly release the result of any revisions to such forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.


Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki